The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry

Published: September, 2015 Authors:Sumudu K. Narayana, Karla J. Helbig,Erin M. McCartney, Nicholas S. Eyre, Rowena A. Bull, Auda Eltahla, Andrew R. Lloyd and Michael R. Beard Source: Journal of Biology Chemistry Abstract:The interferon-induced transmembrane (IFITM) family of proteins have recently been identified as important host effector molecules of the type…

Read More

Gilead Seeks FDA Approval for Hep C Treatment for All Genotypes

October 30, 2015 Gilead Sciences has filed a new drug application with the U.S. Food and Drug Administration (FDA) for approval of the once-daily, fixed-dose combination tablet of Sovaldi (sofosbuvir) and the investigational drug velpatasvir to treat those with genotypes 1 through 6 of hepatitis C virus (HCV). The application…

Read More

New Generic Sofosbuvir for Hepatitis C Treatment in Morocco

October 29, 2015 A generic version of hepatitis C virus (HCV) treatment sofosbuvir will soon hit the market in Morocco at a much lower cost than existing brand-name versions of the pill, Morocco World News reports. The soon-to-be-released “100% Moroccan” drug—which contains the same active ingredients as Gilead Sciences’ brand-name…

Read More

Hepatitis C Treatments Viekira Pak and Technivie May Cause Liver Damage

October 23, 2015 The U.S. Food and Drug Administration (FDA) has required AbbVie to change the labels for its two hepatitis C virus (HCV) treatments after receiving numerous reports of serious liver injury developing among people while taking the medications, Medscape reports. Previously, the labels for Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir)…

Read More

Opioid Substitution Therapy Reduces Hepatitis C Risk

October 26, 2015 Injection drug users (IDUs) who participate in opioid substitution therapy (OST) programs are at lower risk of contracting hepatitis C virus (HCV), especially if they also receive significant injection supplies from a needle exchange program (NEP), aidsmap reports. These findings, the result of a systematic review of…

Read More

FDA warns of deadly liver damage with AbbVie hepatitis drugs

Oct 22, 2015 WASHINGTON (AP) — Federal health officials are warning doctors and patients that two hepatitis C drugs from AbbVie can cause life-threatening liver injury in patients with advanced forms of the disease. The Food and Drug Administration said Thursday it will require AbbVie to add new warnings to…

Read More

BMS to Fund Three Research Projects Seeking HIV and Hepatitis Cures

October 23, 2015 Bristol-Myers Squibb has announced the 2015 recipients for three $300,000 research grants under its Partnering for Cure program, which this year, will go toward providing new insights on the immunopathology of HIV and the hepatitis B virus (HBV), according to a recent press release from the pharmaceutical…

Read More